Innate Pharma
IPHA
13 hedge funds and large institutions have $3.2M invested in Innate Pharma in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0.56% less ownership
Funds ownership: 1.76% → 1.19% (-0.56%)
19% less funds holding
Funds holding: 16 → 13 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
51% less capital invested
Capital invested by funds: $6.52M → $3.2M (-$3.32M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$400K |
| 2 |
Jane Street
New York
|
+$84.9K |
| 3 |
Morgan Stanley
New York
|
+$20.8K |
| 4 |
Barclays
London,
United Kingdom
|
+$12.6K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$3.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$839K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
-$547K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$364K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$265K |
| 5 |
Two Sigma Investments
New York
|
-$114K |
IPHA Hedge Fund Activity: Q1 2022 in Review
13 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2022, worth a combined $3.2M — down 51% from $6.52M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IPHA and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was BlackRock, adding an estimated $400K. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $839K sold.
- 13 institutional investors held Innate Pharma (IPHA) as of Q1 2022, down from 16 in Q4 2021.
- Funds reported $3.2M of Innate Pharma stock for Q1 2022, down 51% quarter-over-quarter.
- 2 funds opened new Innate Pharma positions in Q1 2022 and 5 closed out, a net change of -3 holders.
- The largest Innate Pharma buyer in Q1 2022 was BlackRock, an estimated $400K added.
- The largest Innate Pharma seller in Q1 2022 was Silverarc Capital Management, an estimated $839K sold.
Based on aggregated 13F filings for Q1 2022.